Business Context and Reporting Period
Bon Natural Life Limited, a bio-ingredient solutions provider based in Xi'an, China, announced its unaudited interim financial results for the six months ended March 31, 2024. The filing was submitted on September 27, 2024. The company manufactures functional active ingredients extracted from natural herb plants for the functional food, personal care, cosmetic, and pharmaceutical industries.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2024 | Six Months Ended Mar 31, 2023 |
|---|---|---|
| Revenue | $10,183,553 | $14,149,967 |
| Gross Profit | $2,968,437 | $4,717,348 |
| Gross Margin | 29.1% | 33.3% |
| Operating Income | $84,505 | $2,985,234 |
| Net (Loss) Income | ($41,798) | $2,102,656 |
| EPS (Basic) | $0.00 | $0.24 |
| Cash and Cash Equivalents (End of Period) | $717,879 | $542,272 |
| Net Cash Used in Operating Activities | ($1,884,173) | ($2,177,992) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 28.0% ($3.97 million) year-over-year. This was driven by an 87.3% drop in fragrance compound sales and a 53.6% drop in health supplement sales, partially offset by a 160.9% surge in bioactive food ingredient sales.
- Profitability Collapse: Operating income plummeted 97.2% to $84,505. The company swung from a net income of $2.1 million in the prior period to a net loss of $41,798.
- Expense Increases: General and administrative expenses rose 29.0% due to a 59.6% increase in professional service and consulting fees. Research and development expenses surged 584.9% primarily due to a significant increase in outsourcing R&D activities.
- Customer Concentration: Customer count decreased from 94 to 81. Revenue concentration increased, with two customers accounting for 78.2% of total revenue in 2024, compared to three customers accounting for 90.4% in 2023.
- Currency Impact: Foreign currency fluctuations (RMB to USD) had a negative impact of approximately 3.3% on reported revenue and costs.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management is actively shifting sales strategy to focus on the bioactive food ingredients segment, specifically milk thistle extracts, while reducing emphasis on fragrance compounds and health supplements due to declining market demand.
- Liquidity Position: Despite operating cash outflows, the company ended the period with a net increase in cash of $605,128, funded primarily by net proceeds from short-term and long-term loans totaling over $4.4 million.
- Risk Factors: The filing highlights ongoing uncertainties related to the potential resurgence of COVID-19, which could disrupt supply chains and customer contracts. Additionally, the company notes high customer concentration risk and reliance on foreign exchange rates.
- Forward-Looking Statements: Management cautions that actual results may differ materially from projections due to competitive pressures, raw material price volatility, and regulatory changes.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the two top customers who now represent 78.2% of revenue.
- R&D Capitalization vs. Expense: Confirm the nature of the $788,879 increase in outsourced R&D and whether these costs are recurring or one-time project fees.
- Debt Servicing: Assess the company's ability to service the increased debt load used to fund operations, given the shift to net loss.
- Inventory Levels: Review the $498,736 increase in inventory to ensure it aligns with anticipated sales orders and does not indicate obsolescence.
- Product Mix Transition: Monitor the sustainability of the 160.9% growth in bioactive food ingredients to determine if it can fully offset the decline in legacy product lines.